In patients with HFpEF and concomitant AF, beta-blocker therapy is associated with significant reductions in all-cause and cardiovascular mortality and a permissive clinical approach to beta-blocker use is supported, particularly for rate control in those with elevated heart rates.
Shahrukh Mohammed, Khubaib Mohammad Murtafa, Rohit Vondivillu Srinivasan et al.· Irish Journal of Medical Sci...· 0 citations
Background:
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of HF cases, predominantly affecting older adults with comorbidities such as hypertension, diabetes, and obesity. Despite the breakthrough provided by angiotensin receptor-neprilysin inhibitors (ARNI), approximately 30%...
Yong Il Ho, Zhi-Quan Wang, Jong-Suk Mun et al.· Bulgarian Cardiology· 0 citations
In HFpEF, beta-blocker discontinuation improved functional capacity and quality-of-life at 2 weeks compared with continuation with no clear effect on cognition, echocardiographic parameters or CV biomarkers, but findings on important long-term clinical outcomes was conflicting.
Wade Thompson, Nima Alaeiilkhchi, Lisa M. McCarthy et al.· Journal of Cardiac Failure· 0 citations
Background:
Heart rate (HR) reduction is commonly proposed to improve diastolic fi lling and reduce left ventricular (LV) fi lling pressure in heart failure with preserved ejection fraction (HFpEF). Ivabradine selectively lowers HR without direct myocardial effects, providing a mechanistic model to examine whether HR...
I. Wedharga, M. Hendri, M. Sanusi et al.· Bulgarian Cardiology· 0 citations
SGLT2 inhibitor use in heart failure with reduced ejection fraction was associated with significantly improved long-term survival and a substantial reduction in heart failure and acute coronary syndrome hospitalizations, without increased risk of AKI or UTI.
Jonathan Zawadzki, Ronit Kar, G. Bailey et al.· Journal of Clinical Cardiolo...· 0 citations